Corcept Therapeutics reported Part A results from its Phase 2 BELLA trial of Lifyorli in 95 women with platinum-resistant ovarian cancer. Lifyorli plus nab-paclitaxel and bevacizumab showed longer median progression-free survival and a higher overall response rate than Lifyorli plus nab-paclitaxel in the separate ROSELLA study. No new safety signals emerged. Results looked stronger in patients who had not previously received bevacizumab, which could shape how Corcept positions the drug. BELLA is a single-arm study, and Lifyorli is not approved with bevacizumab. Corcept must fund confirmatory work while Korlym generic competition and heavy spending pressure margins. Analysts forecast revenue of $2.3 billion and earnings of $953.1 million by 2029, up from $54.3 million in earnings today.

October 2026's top insider-owned growth stocks. October 21, 2026 Over the last 7 days, the United States market has remained flat, yet it is up 12% over the past year with earnings forecast to grow by 17% annually. In this environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those closest to the business in its future potential. Top 10 growth companies with high Insider Ownership in the United States. | Name | Insider Ownership | Earnings Growth | | Upstart Holdings (UPST) | 14.0% | 70.2% | | Standard Nuclear (STDN) | 20.4% | 64.2% | | Sable Offshore (SOC) | 11.3% | 71.3% | | Precigen (PGEN) | 11.7% | 54% | | Nu Holdings (NU) | 23.1% | 22.3% | | Karman Holdings (KRMN) | 13.6% | 56.4% | | Himax Technologies (HIMX) | 29.1% | 70.2% | | Figure Technology Solutions (FIGR) | 21.4% | 33.1% | | Energy Vault Holdings (NRGV) | 10.5% | 67.3% | | Almonty Industries (ALM) | 10.8% | 58.3% | Let's take a closer look at a couple of our picks from the screened companies. Simply Wall St Growth Rating: Overview: Corcept Therapeutics Incorporated is a biopharmaceutical company focused on discovering and developing medications for severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States, with a market cap of $12.60 billion. Operations: The company's revenue primarily comes from the discovery, development, and commercialization of pharmaceutical products, amounting to $830.81 million. Insider Ownership: 10.7% Corcept Therapeutics, with high insider ownership, is positioned for growth as its earnings are forecasted to grow significantly at 43.4% annually and revenue at 25.6%, outpacing the US market. Recent endorsements from diabetes associations highlight the potential of its drug mifepristone for managing hyperglycemia in type 2 diabetes patients. However, profit margins have declined from last year, and there has been significant insider selling recently. Simply Wall St Growth Rating: Overview: Nuvation Bio Inc. is a clinical-stage biopharmaceutical company dedicated to developing cancer treatment product candidates, with a market cap of $1.57 billion. Operations: The company generates revenue from oncology development activities, amounting to $169.90 million. Insider Ownership: 18.9% Nuvation Bio, characterized by high insider ownership, is poised for substantial growth with its revenue projected to grow 31.4% annually, outpacing the US market. The recent FDA approval of IBTROZI enhances its position in treating ROS1+ NSCLC. Despite a net loss of US$62.84 million in Q2 2026, the company forecasts profitability within three years and trades significantly below estimated fair value. Safety concerns include hepatotoxicity and QTc prolongation associated with IBTROZI use. Simply Wall St Growth Rating: Overview: Standard Nuclear, Inc. operates as an independent advanced nuclear fuel company in the United States with a market cap of $1.92 billion. Operations: The company generates revenue primarily from its TRISO Production segment, which amounts to $7.54 million. Insider Ownership: 20.4% Standard Nuclear, with significant insider ownership, is positioned for robust growth as its revenue is forecast to increase by 62% annually, surpassing the US market. Recent agreements with Antares and Radiant Industries secure long-term TRISO fuel supply, enhancing its domestic nuclear capabilities. Despite a net loss of US$3.42 million in Q2 2026, the company plans to achieve profitability within three years while trading well below estimated fair value. Facility expansions in Tennessee and Idaho further bolster production capacity. Key takeaways. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years. Valuation is complex, but we're here to simplify it. Discover if Nuvation Bio might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

2026 Patient Innovators Awards winners announced at Courier Health's annual Summit. Oct 13, 2026, 09:00 ET Honorees celebrated as biopharma gathered in New York City to chart the future of the patient experience NEW YORK, Oct. 13, 2026 /PRNewswire/ - Courier Health, the leading technology company for managing patient experiences, today announced the winners of the second annual Patient Innovators Awards, which recognize the biopharma teams and leaders going above and beyond to improve patient access, innovation, and overall outcomes. Winners were announced live on October 6th at the third annual Patient Innovators Summit in New York City. The invite-only event brought together Patient Services, Access & Reimbursement, and Commercial IT & Analytics leaders from more than 75 biopharma companies. Together, attendees represented more than 100 disease states and roughly 35 million patients with previously unmet needs. Four teams and one individual were recognized for driving innovation and measurably improving the patient experience: * Rare Disease Champions of the Year: KalVista, a Company of Chiesi Group * Patient Services Team of the Year: Priovant Therapeutics * Field Access Team of the Year: UCB, Inc. * Patient Champion of the Year: Rob Chuba, Alkermes * Patient Innovators of the Year: Bristol Myers Squibb's CAR T-cell therapy Patient Access Support Services (PASS) team "Being named Patient Services Team of the Year is a testament to the team and program we're building," said Lee Liberator, Vice President of Patient Services and Reimbursement at Priovant Therapeutics. "We've built a unique program centered around what patients actually need from us, and we're proud to be recognized for our commitment to innovating and championing a better patient experience." In his opening keynote, Danny Sigurdson, Founder and CEO of Courier Health, described the moment as a fork in the road. As manufacturers take greater internal control of their programs, data ownership, outcomes-based measurement, and AI-enabled workflow innovation have become critical. Organizations that invest in the right foundation will gain greater operational leverage to focus on their core competency - supporting patients and providers - while those that don't will fall further behind. "This year's Patient Innovators Awards winners are proof that a better path, and a brighter future, is already being built," said Danny Sigurdson. "These teams and our individual Patient Champion of the Year aren't afraid to challenge the status quo and rethink how their programs run. They never lose sight of the patient, and it's an honor to recognize their contributions." This year's Patient Innovators Summit featured 11 industry speakers from companies including Alkermes, Beren Therapeutics, Corcept Therapeutics, Compass Pathways, Dyne Therapeutics, Genentech, and Tarus Pharmaceuticals. The audience also heard a powerful firsthand story from Mark Dant, rare disease advocate and Volunteer Executive Director for the Ryan Foundation. About Courier Health Courier Health is a New York City-based technology company on a mission to improve the patient experience for hundreds of millions of people living with a chronic condition or rare disease. The company develops and delivers the fastest-growing patient experience solution for the life sciences industry. Companies that choose Courier Health are achieving double-digit improvements to patient starts, time-to-start and ongoing adherence to life-altering therapies. As host of the invite-only Patient Innovators Summit and publisher of The State of Patient-Centricity in Biopharma report, Courier Health is backed by leading investors, including Oak HC/FT, Norwest and Work-Bench. Follow Courier Health on LinkedIn and learn more at www.courierhealth.com. SOURCE Courier Health